CN110652515A

CN110652515A - Application of AMPK inhibitor Compound C in tumor treatment drug

Info

Publication number: CN110652515A
Application number: CN201810695505.2A
Authority: CN
Inventors: 万晓春; 黄诗然; 章桂忠
Original assignee: Shenzhen Institute of Advanced Technology of CAS
Current assignee: Shenzhen Institute of Advanced Technology of CAS
Priority date: 2018-06-29
Filing date: 2018-06-29
Publication date: 2020-01-07
Also published as: WO2020000704A1

Abstract

The invention discloses a new application of an AMPK inhibitor Compound C. In particular to the application of Compound C inhibitor in preparing the medicine for treating tumor. Compund C can exert the function of resisting tumors of the blood system by inhibiting the activity of tumor cells and inducing the apoptosis of the tumor cells. The new application of the AMPK inhibitor Compound C provided by the invention provides a new medicine for clinical treatment of tumors in a blood system.

Description

Application of AMPK inhibitor Compound C in tumor treatment drug

Technical Field

The invention belongs to the technical field of medicines, and particularly relates to an application of an AMPK inhibitor Compound C in a medicine for treating tumors.

Background

Tumors (tumors) are a non-genetic disease of the gene. Under the action of tumorigenic factors, the gene of normal cells is changed, and the normal regulation and control of the growth of the cells are lost, so that abnormal hyperplasia is caused. Tumor cells have three significant basic features: immobility, migration and loss of contact inhibition. The core idea of tumor therapy is to kill and eliminate tumor cells.

One of the action mechanisms of the current clinical tumor treatment means, such as chemotherapy, radiotherapy, hormone therapy and some biological therapies, is to induce tumor cells to undergo apoptosis. For example, apoptosis caused by radiotherapy is mainly mediated by Fas, and some cell cycle related proteins, Bcl-2 and Bax, play a key role in the process. Chemotherapy is the treatment of tumor by inducing tumor cells to undergo apoptosis with some chemical drugs. Drugs such as doxorubicin, 5-fluorouracil, etc. are effective in causing cellular DNA damage, resulting in cell G1 phase cycle arrest to complete repair or to enter apoptosis. And paclitaxel, colchicine, etc. acting on microtubules mediate apoptosis through Bcl-2 family. Chemotherapy is still one of the main strategies for cancer treatment at the present stage and for some time in the future. The toxic and side effects are great, and the generation of drug resistance is a main obstacle facing the tumor chemotherapy.

Therefore, no matter radiotherapy or chemotherapy, the targeting property is lacked when the tumor cell apoptosis is induced, the life of normal cells is harvested while the tumor cells are killed, and the toxic and side effects are great. In addition, tumor recurrence and drug resistance occur frequently after radiotherapy and chemotherapy, and the clinical treatment effect is also severely limited. At present, the treatment effect of the tumor is poor, the five-year survival rate of patients is very low, and a new high-efficiency and low-toxicity therapy is urgently needed.

Compound C (Dorsomorphin) is a potent, reversible selective AMPK inhibitor, competing for its ATP binding site. Ki was 109nM in cell-free assays. Studies have shown that Compound C selectively inhibits AMPK activity, while there is no significant inhibition of some other structurally related kinases, including ZAPK, SYK (sole Tyrosine Kinase), PKC θ (Protein Kinase C- θ), pka (Protein Kinase a), and JAK3(Janus Kinase 3). Thus, while Compound C is currently used in the art as a specific AMPK inhibitor, no other new uses for Compound C, such as its use in treating tumors, have been found.

Disclosure of Invention

The invention aims to overcome the defects of the prior art and provide an application method of an AMPK inhibitor Compound C, so as to solve the technical problems that the current Compound C is only used for specific AMPK inhibitors and the current methods and medicines for treating cancers have large side effects and are easy to generate drug resistance and the like.

The invention also aims to provide a medicament for treating tumors, which solves the technical problems that the existing medicament for treating tumors has toxic or side effect, is easy to generate drug resistance, is easy to relapse and the like.

In order to achieve the above object, according to one aspect of the present invention, there is provided a method for using the AMPK inhibitor Compound C. In particular to application of the AMPK inhibitor Compound C in preparing a medicine for treating tumor.

In another aspect of the invention, a medicament for treating tumors is provided. The medicament for treating the tumor comprises an effective dose of active ingredients for treating the tumor, and the active ingredients comprise AMPK inhibitor Compound C.

Compared with the prior art, the application of the AMPK inhibitor Compound C in the preparation of the tumor treatment drug has the following beneficial effects:

experiments prove that the AMPK inhibitor Compound C has relatively strong effects of inhibiting the activity of tumor cells and inducing the apoptosis of the tumor cells, and plays a role in resisting tumors of a blood system. Therefore, after the AMPK inhibitor Compound C is used as an active ingredient to prepare a tumor treatment drug, the tumor treatment drug can be endowed with remarkable effects of inhibiting tumor cell activity and inducing tumor cell apoptosis.

The medicine for treating tumor takes the AMPK inhibitor Compound C as an active ingredient, so that the medicine for treating tumor can effectively inhibit the activity of tumor cells, induce and promote the apoptosis of the tumor cells, relieve and alleviate the harm of malignant tumor to human body, relieve clinical symptoms, improve the quality of life and prolong life.

Drawings

The invention will be further described with reference to the accompanying drawings and examples, in which:

FIG. 1 is a graph of the effect of Compound C and Rapamycin reagents at various concentrations on the activity of Jurkat lymphoma cells in example 11 of the present invention;

FIG. 2 is a graph showing the effect of different concentrations of Compound C and Rapamycin reagents on the activity of K562 lymphoma cells in example 11 of the present invention;

FIG. 3 is a graph of the effect of Compound C and control reagent (DMSO) on the apoptosis of Jurkat lymphoma cells in example 12 of the present invention;

FIG. 4 is a graph showing the effect of Compound C and control reagent (DMSO) on K562 lymphoma cell apoptosis in example 12 of the present invention.

Detailed Description

In order to make the technical problems, technical solutions and advantageous effects to be solved by the present invention more clearly understood, the present invention is further described in detail below with reference to the following embodiments and the attached tables. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.

Interpretation of the nomenclature:

tumors (tumor, neoplasms): it refers to a new organism (neograwth) formed by local tissue cell proliferation under the action of various tumorigenic factors, because the new organism is mostly in an occupied block-shaped protrusion, also called neoplasms (neoplasms).

Compound C (Dorsomorphin): a potent, reversible, selective AMPK inhibitor with a Ki of 109nM in a cell-free assay. The molecular structure formula is as follows:

AMPK (Adenosine Monophospho-activated Protein Kinase): is a key sensor of cell energy. The protein kinase can maintain the balance of ATP production and consumption of eukaryotic cells by sensing the energy state of the cells, i.e., energy homeostasis, and its activation helps correct metabolic disorders and drive cellular metabolism toward physiological equilibrium, thereby becoming a possible target for the treatment of metabolic disorders and cancer. Many studies have shown that AMPK activation stimulates the body to produce ATP, providing energy for physiological activities; at the same time, AMPK activation strongly inhibits protein and fat synthesis to reduce ATP consumption. Among them, inhibition of AMPK activity by Dorsomorphin almost completely inhibited autophagic proteolysis in HT-29 cells.

In one aspect, the embodiments of the present invention provide methods for the use of the AMPK inhibitor Compound C. In particular to application of the AMPK inhibitor Compound C in preparing a medicine for treating tumor. Relevant experiments show that the AMPK inhibitor Compound C is an active ingredient, and can effectively inhibit the activity of tumor cells and induce and promote the apoptosis of the tumor cells. Specifically, the effect of Compound C at different concentrations on the activity of blood tumor cells in example 1 and the results of the experiment are described below. Therefore, the AMPK inhibitor Compound C can be used as an anti-tumor effective component to inhibit the activity of tumor cells, induce and promote the apoptosis of the tumor cells, so as to achieve the clinical effects of relieving and alleviating the harm of malignant tumors to human bodies, relieving clinical symptoms, improving the quality of life and prolonging the life.

In one embodiment, the tumor in which the AMPK inhibitor Compound C is capable of inhibiting tumor cell activity and promoting tumor cell apoptosis may be a hematological tumor, i.e. the AMPK inhibitor Compound C can be used in the preparation of a medicament for treating a hematological tumor. In particular embodiments, the hematological tumor comprises at least one of a lymphoma, a myeloid leukemia, a myeloma. Wherein the lymphoma comprises T/B lymphoma.

Of course, the AMPK inhibitor Compound C may be other types of tumors besides being able to inhibit the activity of hematological tumor cells and promote apoptosis of hematological tumor cells.

In addition, when the AMPK inhibitor Compound C is used for preparing a medicament for treating tumors, corresponding dosage forms can be prepared according to different administration modes. The AMPK inhibitor Compound C can be compounded with pharmaceutically acceptable components of corresponding dosage forms, such as auxiliary materials and the like, and also can be compounded with other antitumor active ingredients to form the antitumor Compound active ingredient.

In addition, according to the molecular structural formula of Compound C, it is within the scope of the disclosure that other groups, such as substitution modification of hydrogen of carbon atom, are introduced by appropriate modification of the molecular bulk.

On the other hand, based on the application of the AMPK inhibitor Compound C, the embodiment of the invention also provides a medicine for treating tumors. The medicine for treating the tumor comprises an effective dose of active ingredients for treating the tumor, and can further comprise pharmaceutically acceptable auxiliary ingredients. The effective dose refers to an effective amount for treating a tumor, and refers to an amount of a compound of the present invention sufficient to show benefit or clinical significance to an individual. One skilled in the art will appreciate that the actual amount or dose administered and the time course of administration will depend on the nature and severity of the disease being prevented or treated, the age and general condition of the subject being prevented or treated, and the mode of administration, among other factors.

Wherein the active ingredient comprises the AMPK inhibitor Compound C; of course, as noted above, the active ingredient may also include other active ingredients that are effective against tumors, where "effective" as used herein is an ingredient that is clinically effective against tumors alone or in combination with the AMPK inhibitor Compound C to enhance the clinical effect of the AMPK inhibitor Compound C against tumors. In one embodiment, the AMPK inhibitor Compound C is present in the agent for treating tumors in an amount of 5 to 20 μ M.

The auxiliary components can be related auxiliary materials of corresponding dosage forms prepared according to the drug administration mode for treating the tumor. In one embodiment, the adjuvant is a pharmaceutically acceptable carrier for the AMPK inhibitor Compound C. In particular embodiments, the carrier comprises at least one of an antibody capable of coupling to AMPK inhibitor Compound C, a targeted recombinant protein, a nanoparticle, and an exosome. The carrier can improve the stability of the AMPK inhibitor Compound C and the in-vivo targeted administration effect, and even can realize the purpose of targeted killing of tumor cells.

Therefore, the medicine for treating the tumor takes the AMPK inhibitor Compound C as an active ingredient, so that the medicine for treating the tumor can effectively inhibit the activity of tumor cells and induce and promote the apoptosis of the tumor cells, thereby relieving and alleviating the harm of malignant tumors to human bodies, relieving clinical symptoms, improving the quality of life and prolonging the life.

In addition, the medicament for treating the tumor can be prepared according to a conventional medicine preparation method, and if the medicament for treating the tumor contains an antibody capable of being coupled with the AMPK inhibitor Compound C, the antibody can be coupled with the AMPK inhibitor Compound C according to a conventional method.

Now, the application of Compound C in the preparation of a drug for treating tumor will be described in further detail with reference to specific examples.

1. Examples of the Effect of Compound C on tumor cell Activity and apoptosis

Example 11

MTS test for influence of different concentrations of Compound C on blood tumor cell activity

S11 cell pretreatment

1) Two lymphoma cells (Jurkat, K562) were resuspended at 5X 10⁴cells/mL, inoculated in 96-well plates, respectively;

2) adding Compound C into a 96-well plate respectively, setting concentration gradients of 0 mu M, 0.5 mu M, 1 mu M, 5 mu M, 10 mu M and 20 mu M, and detecting the survival condition of cells after culturing for 48 h;

s12 MTS assay for cellular Activity

1) Gently and uniformly mixing 2mL of MTS and 100 mu L of PMS;

2) adding 20 mu of LMTS mixed solution into each hole, fully and uniformly mixing, placing in a carbon dioxide cell incubator, and incubating for 3 hours in a dark place;

3) detecting the wavelengths at OD490nm and OD630nm by using a microplate reader;

4) cell viability was analyzed at each concentration gradient using OD at Compound C concentration of 0. mu.M as a control.

The same comparative example was made as in example 11, using Rapamycin reagent as a control. Experimental examination revealed that Compound C and Rapamycin reagents have the effects on the activity of Jurkat lymphoma cells as shown in FIG. 1, and Compound C and Rapamycin reagents have the effects on the activity of K562 lymphoma cells as shown in FIG. 2. As can be seen from fig. 1 and 2, Compound C has a significant effect of inhibiting the activity of blood tumor cells, and has a stronger ability to inhibit the activity of tumor cells than rapamycins at the same dose.

Example 12

Experiment for analyzing influence of Compound C on tumor cell apoptosis by flow cytometry

S11 cell pretreatment

1) Lymphoma cells (Jurkat, K562) were resuspended to 3X 10⁵cells/mL, seeded in 12-well plates;

2) adding Compound C to culture for 48h, and detecting the apoptosis condition;

s12 flow cytometry analysis of apoptosis

1) Collecting the cell suspension;

2) centrifuging 800g of cell suspension at 4 ℃ for 5min, discarding supernatant, and collecting cells in precipitate;

3) the cells were washed 2 times with pre-chilled PBS and then resuspended in 100. mu.L of 1 × AnnexinV Binding Buffer;

4) adding 5 mu L Annexin V-FITC and 5 mu L PI dye solution into each sample, gently mixing uniformly, and reacting for 15min at room temperature in a dark place; setting single dyeing and blank contrast, and adjusting and compensating the demand by subsequent flow detection;

5) after the incubation is finished, 400 mu L of precooled 1 × Annexin V Binding Buffer is added into each sample and mixed gently; detecting within 1 h;

6) detecting the apoptosis condition by a flow cytometer: the cells with single positive of Annexin V-FITC are early apoptosis cells, and the cells with double positive of Annexin V-FITC/PI are late apoptosis cells.

The same comparative example was carried out as in example 12, using DMSO reagent as a control (Ctrl). According to experimental examination, Compound C and the control group (Ctrl) have the apoptosis effect on the Jurkat lymphoma cells as shown in FIG. 3, and Compound C and the control group (Ctrl) have the apoptosis effect on the K562 lymphoma cells as shown in FIG. 4. As can be seen from fig. 1 and 2, Compound C has a significant apoptotic effect on Jurkat, K562.

The above-described embodiments are merely preferred embodiments of the present invention, which should not be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention should be included in the scope of the present invention.

Claims

The application of AMPK inhibitor Compound C in preparing a medicine for treating tumor.
2. Use according to claim 1, characterized in that: the tumor treating medicine is a blood tumor treating medicine.
3. Use according to claim 2, characterized in that: the hematological tumor comprises at least one of T/B lymphoma, myeloid leukemia and myeloma.
4. A medicament for treating tumors comprises an effective tumor treating dose of active ingredients, and is characterized in that: the active ingredient comprising the AMPK inhibitor Compound C according to any one of claims 1 to 3.
5. The medicament of claim 4, wherein: the content of the AMPK inhibitor Compound C is 5-20 mu M.
6. The medicament according to claim 4 or 5, characterized in that: also included is a pharmaceutically acceptable carrier for said AMPK inhibitor Compound C.
7. The medicament of claim 6, wherein: also included is a pharmaceutically acceptable carrier for said AMPK inhibitor Compound C. The carrier comprises at least one of an antibody coupled with AMPK inhibitor Compound C, a targeting recombinant protein, a nanoparticle and an exosome.